[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arteriovenous-fistula\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arteriovenous-fistula":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,52,83,114,141,181,204,230,256,283,311],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100604778","pivotal-study-of-the-velocity-pavf-system-100604778",false,"NCT07153939","Pivotal Study of the Velocity™ pAVF System","Multicenter Pivotal Study of the Velocity™ Percutaneous Arterio-Venous Fistula System","VENOS-3","Inclusion Criteria:\n\n1. ESRD requiring hemodialysis access or CKD with anticipated need for hemodialysis within 6 months\n2. Cubital perforating vein diameter ⩾ 2.0 and ⩽ 5.0 mm\n3. Proximal radial artery diameter ⩾ 2.0 and ⩽ 4.0 mm\n4. Age \\> 18 years and \\\u003C 80 years\n5. Willing and competent to give written informed consent\n6. Willing and able to complete all study assessments and follow-up requirements\n\nExclusion Criteria:\n\n1. Study extremity systolic blood pressure \\\u003C 100mmHg\n2. Subjects with occlusion of the ulnar or radial artery at any level or an abnormal Allen's test\n3. Subjects with a previous ipsilateral arterio-venous graft or previous ipsilateral upper arm AVF.\n4. Distance between Cubital Perforating Vein and Proximal Radial Artery \\> 3.0 mm\n5. Cephalic vein diameter \\\u003C 2.5 mm at any point from the CPV to the axillary vein\n6. Central venous occlusion ipsilateral of the study extremity\n7. Severe calcification of the radial artery that significantly impairs ultrasound visualization (e.g., acoustic shadowing) and thus precludes safe or accurate device deployment.\n8. Evidence of active systemic infections or localized to the procedure access site within the past 7 days\n9. History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months prior to study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina\n10. Any contraindication to antiplatelet therapy\n11. Currently being treated with another investigational device or drug\n12. Known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated\n13. Uncontrolled or poorly controlled diabetes defined as a HbA1C \\> 10%\n14. Known hypercoagulable condition, bleeding diathesis or coagulation disorder\n15. Lymphedema of the study extremity\n16. Scheduled kidney transplant within 6 months of enrollment\n17. Peripheral white blood cell count \\\u003C 1,500 cells\u002FμL or \\> 13,000 cells\u002FμL and neutrophil \\> 80%\n18. Platelet count \\\u003C 75,000 cells\u002F μL\n19. Current diagnosis of carcinoma (unless in remission \\> 1 year)\n20. Pregnant or currently breast feeding\n21. Allergies to nickel or nickel titanium alloy (NiTi) or any of the components of the Velocity Implant or Delivery System\n22. Any other medical condition that in the opinion of the investigator would put the welfare of the subject at risk or confound interpretation of the study data\n23. Investigator determines that vascular anatomy at intended index procedure site is inappropriate for use of investigational device prior to attempting needle access.","ALL","18 Years","80 Years",{"count":21,"type":22},126,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used.\n\nThe Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis.\n\nThe study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years.\n\nTaking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.",[28,29,30,31],"Chronic Kidney Disease","Hemodialysis Access","Arteriovenous Fistula","End Stage Renal Disease (ESRD)",[33,34,35,36,30,37,15,38],"percutaneous AVF","pAVF","endovascular AVF","endoAVF","AVF","VENOS3","RECRUITING","2026-06-13",{"date":42,"type":43},"2026-06-16","ACTUAL",{"date":45,"type":43},"2025-10-21",{"date":47,"type":22},"2030-09",{"name":49,"class":50},"Venova Medical","INDUSTRY",12,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100523693","cera-vascular-plug-system-post-market-clinical-follow-up-100523693","NCT06099015","Cera™ Vascular Plug System Post-Market Clinical Follow-Up","Cera™ Vascular Plug System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Observational, Single-arm, Open-label, Post-market Study","Inclusion Criteria:\n\n1. Aged 18 to 85;\n2. Life expectancy \\> 1 year;\n3. Require arterial or venous embolization in the peripheral vasculature;\n4. Target embolization site(s) allow for safe insertion of the delivery catheter;\n5. Voluntarily sign and date the Informed Consent Form (ICF) prior to any study-related activities commencement;\n6. Willing and able to comply with protocol requirements, including all study visits and procedures.\n7. Patients for whom the doctor has decided to use the Cera Vascular Plug System, regardless of the study.\n\nExclusion Criteria:\n\n1. The subject is pregnant or plan to be pregnant or breast feeding;\n2. The subject has a known allergy or hypersensitivity to any of the device materials including: nickel, stainless steel, polytetrafluoroethylene and titanium nitride;\n3. The subject has a known allergy or hypersensitivity to contrast agent;\n4. The subject has uncorrectable coagulopathy;\n5. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and\u002For after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints\n6. The subject has an unresolved systemic infection;\n7. Subject who cannot tolerate general or local anesthesia;\n8. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder;\n9. The subject is participating in other drug or medical device clinical trials;\n10. Any condition (medical or anatomic) making the subject not suitable for transcatheter embolotherapy according to the opinion of the investigator.","85 Years",{"count":61,"type":22},132,"OBSERVATIONAL","The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to:\n\n* confirm the performance\n* confirm the safety\n* identify previously unknown side-effects\n* monitor the identified side-effects (related to the procedures or to the medical devices)\n* identify and analyse emergent risks",[65,66,67,68,30,69],"Aneurysm","Endoleak","Pulmonary Arteriovenous Malformation","Portal Hypertension","Splenic Laceration",[71,72],"Lifetech","Cera Vascular Plug","2026-06-10",{"date":75,"type":43},"2026-06-12",{"date":77,"type":43},"2024-06-21",{"date":79,"type":22},"2028-06-30",{"name":81,"class":50},"Lifetech Scientific (Shenzhen) Co., Ltd.",9,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100635996","effect-of-apiban-therapy-on-avf-maturation-in-esrd-patients-100635996","NCT07559942","Effect of Apiban Therapy on AVF Maturation in ESRD Patients","\"Effect of Perioperative and Short-Term Apixaban Therapy on Arteriovenous Fistula Maturation in Patients With End-Stage Renal Disease: A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of ESRD (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m² or already on dialysis) with plans for hemodialysis.\n* Planned primary upper extremity AVF creation (radiocephalic, brachiocephalic, or brachiobasilic).\n* Suitable vessels on preoperative duplex ultrasound (artery ≥ 2 mm, vein ≥ 2.5 mm without tourniquet).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known bleeding diathesis or hypercoagulable state.\n* Current therapeutic anticoagulation (any indication).\n* Current dual antiplatelet therapy.\n* History of intracranial hemorrhage.\n* Known allergy or hypersensitivity to apixaban.\n* Inability to comply with study protocol or follow-up.",{"count":91,"type":22},190,[25],"End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis \\[1\\]. AVFs offer superior longevity, fewer infectious complications, and lower mortality rates compared to central venous catheters or synthetic grafts \\[2\\]. However, a significant limitation to their widespread success is the high rate of early failure, primarily due to failure to mature (FTM). FTM occurs in 20-40% of AVFs, rendering them unusable for dialysis \\[3\\].\n\nApixaban, a direct factor Xa inhibitor, offers a potential advantage by providing sustained anticoagulation throughout the critical maturation period \\[7\\]. Its predictable pharmacokinetics, oral administration, and favorable safety profile make it an attractive agent for short-term use in this setting \\[8\\]. By reducing microthrombotic events during the first 4-6 weeks following AVF creation, apixaban could potentially improve maturation rates. However, this potential benefit must be weighed against the increased risk of bleeding, hematoma formation, and wound complications that could negatively impact fistula maturation \\[9\\].",[95,96,30,97],"Endstage Renal Disease","Direct Oral Anticoagulants (DOACs)","Arteriovenous Fistula Occlusion",[99,100,101,102],"arteriovenous fistula","maturation","anticoagulation","direct oral anticoagulants","2026-05-02",{"date":105,"type":43},"2026-05-07",{"date":107,"type":43},"2026-01-01",{"date":109,"type":22},"2026-08-31",{"name":111,"class":112},"Combined military hospital lahore","OTHER",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100411237","post-market-surveillance-study-of-the-bd-wavelinq-endoavf-system-100411237","NCT04634916","Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System","A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis","CONNECT-AV","Inclusion Criteria:\n\n1. Subject must be either male or non-pregnant female ≥ 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.\n2. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.\n3. Subject must be willing to comply with the protocol requirements, including clinical follow-up.\n4. Subjects who have established, non-reversible kidney failure, who are currently on dialysis at screening or are in immediate need (within 6 months of endoAVF creation) of dialysis.\n5. Target treatment vein diameter(s) for endoAVF creation ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Venography.\n6. Target treatment artery diameter ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Arteriogram.\n7. Subject has adequate collateral circulation to the hand, in the opinion of the Investigator.\n8. At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the target creation site via a proximal forearm perforating vein.\n\nExclusion Criteria:\n\n1. The subject is in a hypercoagulable state.\n2. The subject has known bleeding diathesis.\n3. The subject has insufficient cardiac output to support a native fistula in the opinion of the Investigator.\n4. Known history of active intravenous drug abuse.\n5. \"Planned\" major surgical procedure within 6 months following index procedure or major surgery within 30 days prior to index procedure.\n6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.\n7. The subject has known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated.\n8. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and\u002F or WBC of ≥ 12,000 cells\u002F μL, if collected).\n9. The subject has another medical condition, which, in the opinion of the Investigator, may cause him\u002Fher to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.\n10. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.\n11. The subject has central venous stenosis or central vein narrowing \\> 50% based on imaging on the same side as the planned endoAVF creation.\n12. Absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via Duplex Ultrasound (DUS) or Venography.\n13. Occlusion or stenosis \\> 50% of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via Duplex Ultrasound (DUS) or Venography.\n14. Significantly compromised venous or arterial flow in the treatment arm as determined by Investigator and Duplex Ultrasound (DUS) or Venography.\n15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the Investigator.",{"count":123,"type":22},280,[25],"A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.",[127,128,30],"Kidney Disease, End-Stage","End-stage Renal Disease",[130],"EndoAVF","2026-03-25",{"date":133,"type":43},"2026-03-27",{"date":135,"type":43},"2021-03-26",{"date":137,"type":22},"2027-09",{"name":139,"class":50},"C. R. Bard",17,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":162,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":149,"type":22},600,[25],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[153,154,30,155,156,157,158,159,160,161],"Chronic Kidney Diseases","End Stage Renal Disease","Hemodialysis Access Failure","ESRD","Vascular Access Complication","Renal Failure","Catheter Complications","Catheter Dysfunction","Renal Insufficiency",[163,164,165,166,167,168,169,170,28,154,30,37],"Vascular Surgery","Vascular Access","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Hemodialysis","Dialysis","2026-02-12",{"date":173,"type":43},"2026-02-17",{"date":175,"type":43},"2024-01-03",{"date":177,"type":22},"2029-12",{"name":179,"class":50},"VenoStent",28,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":113},"100621546","single-needle-distal-return-for-long-term-arteriovenous-fistula-care-100621546","NCT07372027","Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care","A Prospective Study on the Efficacy and Cost-Effectiveness of Modified Single-Needle Distal Return Cannulation for Long-Term Arteriovenous Fistula Care in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n\nDiagnosis of end-stage kidney disease (ESKD) requiring maintenance hemodialysis (three times per week).\n\nReliable use of a native arteriovenous fistula (AVF) as the primary vascular access for at least the past 3 months.\n\nWilling and able to provide written informed consent to participate in the study.\n\nAdequate superficial venous vasculature in at least one lower extremity (e.g., dorsal foot veins, saphenous tributaries) as assessed by clinical evaluation and\u002For bedside ultrasound, deemed suitable for cannulation as a venous return site.\n\nFor the experimental (SNDR) group: Expressed willingness to adopt the single-needle distal return cannulation strategy.\n\nFor the control group: Currently receiving and willing to continue standard two-needle AVF cannulation.\n\nExclusion Criteria:\n\n* Active systemic infection or localized infection at the potential cannulation sites (AVF or lower extremity veins).\n\nKnown severe coagulation disorder or thrombocytopenia (platelet count \\\u003C 50 × 10⁹\u002FL) that would pose a high risk of bleeding complications from cannulation.\n\nSevere peripheral arterial disease or venous insufficiency in the lower extremities that contraindicates venous cannulation or may compromise limb perfusion.\n\nUnstable cardiovascular status (e.g., uncontrolled heart failure, severe arrhythmias) as determined by the treating nephrologist, which would increase the risk associated with any change in dialysis procedure.\n\nDocumented severe cognitive impairment, psychiatric illness, or any condition that would impair the ability to provide informed consent or adhere to the study protocol.\n\nLife expectancy less than 12 months due to non-renal comorbid conditions (e.g., metastatic malignancy).\n\nCurrently pregnant or breastfeeding.\n\nParticipation in another interventional clinical trial that could confound the outcomes of this study.\n\nAnatomical or pathological condition of the AVF (e.g., extreme depth, aneurysm with overlying skin compromise, complete thrombosis) that precludes safe single-needle cannulation, as judged by the study vascular access team.\n\nInability to comply with the scheduled study visits and follow-up assessments.","100 Years",{"count":190,"type":22},100,[25],"Background:\n\nFor millions of people worldwide with kidney failure, a well-functioning vascular access, like an arteriovenous fistula (AVF), is essential for life-sustaining hemodialysis. However, the standard method requires puncturing the same AVF with two needles three times a week, which over time can damage the vessel, leading to scarring, narrowing, and frequent failures. These complications often require repeated surgical or minimally invasive procedures (reinterventions), causing significant pain, high medical costs, and exhaustion of the patient's limited blood vessels.\n\nNew Approach:\n\nThis study will evaluate a modified puncture technique called the Single-Needle Distal Return (SNDR) strategy for long-term AVF care. Instead of using two needles in the AVF, only one needle is placed in the AVF to draw blood. The cleaned blood is then returned to the body through a second needle placed in a superficial vein in the foot or lower leg. This approach aims to reduce trauma to the critical AVF.\n\nStudy Plan:\n\nThis is a clinical study conducted at the Blood Purification Center of Anhui Medical University Affiliated Suzhou Hospital. We plan to enroll approximately 50 adult hemodialysis patients who use an AVF and are willing to try the SNDR technique. For comparison, we will also observe data from a similar number of patients receiving standard two-needle AVF care during the same period.\n\nThe study will last about three years. We will closely monitor patients using the SNDR technique to assess:\n\nEffectiveness: Whether dialysis remains adequate (measured by Kt\u002FV).\n\nSafety: Rates of complications (like bruising or infection), dialysis machine alarms, and venous pressure during treatment.\n\nPractical Benefits: Whether it reduces the need for repair procedures (reinterventions) and hospitalizations related to the AVF.\n\nEconomic Impact: Changes in healthcare costs.\n\nPatient Experience: Patient tolerance and comfort with the technique. We will also analyze the characteristics of patients who successfully use this technique long-term to help identify who might benefit most from it in the future.\n\nPotential Significance:\n\nIf proven successful and safe for long-term use, the SNDR strategy could help protect a patient's precious AVF, potentially reducing painful procedures, lowering costs, slowing down the exhaustion of blood vessels, and improving the quality of life for people on long-term dialysis. The findings may also guide better planning for vascular access care.",[29,30,194,164,157],"Arteriovenous Fistula Cannulation","2026-01-19",{"date":197,"type":43},"2026-01-28",{"date":199,"type":22},"2026-12-15",{"date":201,"type":22},"2026-12-31",{"name":203,"class":112},"Suzhou Municipal Hospital of Anhui Province",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":113},"100617086","the-liquid-embolic-agent-for-the-treatment-of-brain-arteriovenous-malformation-100617086","NCT07314047","The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation","a Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Controlled Registration Trial of the Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation","PARTNER","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 80 years at the time of signing the informed consent\n* Subjects with brain arteriovenous malformation diagnosed by CT\u002FMRI\u002FDSA\n* The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ \\~ Ⅳ\n* Subjects themselves and\u002For their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form\n* Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator\n\nExclusion Criteria:\n\n* Multiple brain arteriovenous malformations\n* Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period\n* Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years\n* Brain arteriovenous malformation with bleeding within 1 week\n* Brain arteriovenous malformation with an expected number of embolizations ≥ 4\n* Brain arteriovenous malformation scheduled for surgical resection after embolization\n* mRS score ≥ 3\n* Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc\n* Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.) within 30 days prior to signing the informed consent form, or those scheduled for such procedures within 60 days after signing the informed consent form\n* Contraindications for liquid embolic agent treatment, including but not limited to: contraindications for DSA, severe allergy or intolerance to contrast agents, severe allergy or intolerance to antiplatelet or anticoagulant medications required for treatment, or severe allergy to tantalum metal\n* Pregnant or lactating women\n* Subjects participating in other drug or device studies that have not reached their endpoints or who have just withdrawn from the group for less than one month",{"count":213,"type":22},116,[25],"This study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion and exclusion criteria specified in this trial protocol, approximately 116 subjects with brain arteriovenous malformation will be enrolled for interventional embolization treatment. The subjects will undergo follow-up before the surgery, after device implantation, at discharge, 1 month (± 7 days), 6 months (± 30 days), and 12 months (± 60 days) after the first embolization. When necessary, unscheduled follow-up will be conducted to record various indicators for evaluating the safety and effectiveness of liquid embolic agents in the treatment of brain arteriovenous malformations.",[217,30],"Brain Arteriovenous Malformation",[219,99,220],"brain arteriovenous malformation","LIQUID EMBOLIC AGENT","2025-12-30",{"date":223,"type":43},"2026-01-02",{"date":225,"type":43},"2024-05-28",{"date":227,"type":22},"2026-05-28",{"name":229,"class":50},"MicroPort NeuroTech Co., Ltd.",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100604968","the-clinical-application-of-peripheral-embolization-coil-systems-in-arteriovenous-embolization-within-the-peripheral-vasculature-100604968","NCT07156409","The Clinical Application of Peripheral Embolization Coil Systems in Arteriovenous Embolization Within the Peripheral Vasculature","A Prospective, Multicenter, Single-Arm Target Value Study Evaluating the Safety and Effectiveness of a Peripheral Embolization Coil System for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive), regardless of gender;\n2. Patients diagnosed preoperatively via imaging (including but not limited to ultrasound, CTA, MRA, DSA, etc.) with peripheral arteriovenous conditions requiring embolization therapy;\n3. The visually estimated normal reference diameter of the target vessel is ≥ 3mm;\n4. Patients or their legally authorized representatives are capable of understanding the study objectives, voluntarily participating in this study, providing signed informed consent, and able to comply with follow-up.\n\nExclusion Criteria:\n\n1. The target vessel requires the concurrent use of other embolic materials (e.g., Gelfoam, embolic microspheres, liquid embolic agents, etc.);\n2. Known definite history of allergy to platinum, tungsten metals, and\u002For any component of the investigational product;\n3. Subjects with pre-existing severe cardiac, hepatic, renal, respiratory diseases, or coagulation disorders who are unsuitable for anesthesia or endovascular surgical treatment;\n4. High-flow arteriovenous fistulas that may cause migration of the embolic material;\n5. The target aneurysm is a blister aneurysm, dissecting aneurysm, mycotic (infectious) aneurysm, ruptured aneurysm, or aneurysm caused by connective tissue diseases;\n6. Severe vascular stenosis or tortuosity, or anatomical anomalies where it is anticipated that the device will be difficult to navigate to the lesion site, or other uncommon anatomies that may interfere with device use;\n7. The target vessel has undergone any previous embolization therapy or surgical intervention, or has recurrent disease;\n8. Definite allergy, resistance, or contraindication to antiplatelet drugs, anticoagulants, contrast media, and\u002For anesthetics;\n9. Females who are pregnant, breastfeeding, or planning to become pregnant within 6 months; males planning for parenthood within the next 6 months;\n10. Subjects currently participating in other drug or device clinical trials who have not reached the trial endpoint;\n11. Investigators deem the subject unsuitable for participation in this study.","75 Years",{"count":239,"type":22},139,[25],"Evaluation of the Safety and Effectiveness of the Peripheral Embolization Coil System Manufactured by Suzhou Zhongtian Medical Instruments Co., Ltd. for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting",[243,244,30,245],"Peripheral Arterial Hemorrhage","Arteriovenous Malformation","Peripheral Aneurysm","NOT_YET_RECRUITING","2025-09-04",{"date":249,"type":43},"2025-09-05",{"date":251,"type":22},"2025-09",{"date":253,"type":22},"2026-12",{"name":255,"class":50},"Suzhou Zenith Vascular Scitech Co., Ltd.",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100598060","evaluating-the-effect-of-the-valsalva-maneuver-on-invasive-pain-during-arteriovenous-fistula-cannulation-in-hemodialysis-patients-100598060","NCT07066579","Evaluating the Effect of the Valsalva Maneuver on Invasive Pain During Arteriovenous Fistula Cannulation in Hemodialysis Patients","Evaluation of the Effect of the Valsalva Maneuver on Invasive Pain During Arteriovenous Fistula Cannulation in Hemodialysis Patients","VALPAIN-HD","Inclusion Criteria:\n\n* Age 18 years or older\n* Receiving hemodialysis treatment via arteriovenous fistula for at least 3 months\n* No analgesic medication use within the past 24 hours\n* Systolic blood pressure between 90-160 mmHg and diastolic between 60-100 mmHg\n* Pain score ≥ 1 on Visual Analogue Scale during AVF cannulation\n* Able to perform the Valsalva maneuver (no contraindications)\n* No communication barriers or severe psychiatric disorders\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Unable to correctly perform the Valsalva maneuver\n* Failed first cannulation attempt\n* History of acute myocardial infarction or malignant arrhythmia\n* Aneurysm, infection, edema, or scar tissue at AVF site\n* Pregnancy\n* Voluntary withdrawal from the study at any stage\n* Switching dialysis centers or requiring hospitalization during the study",{"count":265,"type":22},60,[25],"The goal of this clinical trial is to evaluate whether the Valsalva maneuver reduces invasive pain during arteriovenous fistula (AVF) cannulation in adult hemodialysis patients. The main questions it aims to answer are:\n\nDoes the Valsalva maneuver effectively reduce pain intensity during AVF cannulation as measured by the Visual Analogue Scale (VAS)?\n\nIs the Valsalva maneuver feasible, acceptable, and satisfactory for patients, and can it be sustainably implemented over multiple sessions?\n\nResearchers will compare patients performing the Valsalva maneuver (intervention group) with those receiving standard care without any intervention (control group) to see if pain scores are significantly lower and whether patients are willing to continue using this technique voluntarily.\n\nParticipants will:\n\nReceive training and supervised practice on the Valsalva maneuver before inclusion in the study\n\nPerform the Valsalva maneuver during AVF cannulation in each hemodialysis session for 12 sessions\n\nComplete VAS pain assessments after each session\n\nComplete a patient satisfaction and feasibility form at the end of the study",[30,269,155,270],"Pain","Vascular Access Device Complications",[169,30,272,273],"Cannulation Pain","Valsalva Maneuver","2025-07-05",{"date":276,"type":43},"2025-07-15",{"date":278,"type":22},"2025-09-01",{"date":280,"type":22},"2026-09-01",{"name":282,"class":112},"Cansu POLAT DÜNYA",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":290,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":113},"100558617","phase-3-randomised-clinical-trial-comparing-drug-coated-balloon-to-plain-balloon-for-all-peripheral-avf-stenosis-100558617","NCT06553443","Randomised Clinical Trial Comparing Drug-coated Balloon to Plain Balloon for All Peripheral AVF Stenosis","RANGER","Inclusion Criteria:\n\n1. Failing AVF with at least 1 AVF stenosis presenting with any clinical, physiological or haemodynamic abnormalities. Both de novo and recurrent stenosis are accepted.\n2. AVF has been used successfully for at least 1 month (non-mature AVF are not allowed).\n3. Less than 30% residual stenosis after angioplasty.\n4. ≥ 21 years old\n5. Informed and valid consent given.\n\nExclusion Criteria:\n\n1. Thrombosed AVFs\n2. Haemodynamically significant central vein stenosis\n3. Target lesion not treatable with the available sizes of drug eluting balloon (up to 8mm)\n4. Contraindication to antiplatelet therapy\n5. Coagulopathy or thrombocytopenia that cannot be managed adequately with periprocedural transfusion.\n6. Allergy \u002F contraindication to paclitaxel.\n7. Acute infection over proposed puncture site.\n8. Women who are breastfeeding, pregnant \\* or planning on becoming pregnant during study.\n9. Participant with medical conditions, which in the opinion of the investigator may cause noncompliance with protocol.\n10. Currently participating in an investigational drug, biologic or device trial that may have an impact on the dialysis access or previous enrolment in this study.","21 Years",{"count":292,"type":22},94,[294],"PHASE3","To compare the access circuit primary patency after Ranger drug-coated balloon angioplasty of arteriovenous fistula (AVF) stenosis with that after conventional balloon angioplasty",[30,297,298],"Arteriovenous Fistula Stenosis","Dialysis Access Malfunction",[300,301],"drug-coated balloon","access circuit patency","2024-08-11",{"date":304,"type":43},"2024-08-14",{"date":306,"type":43},"2024-01-04",{"date":308,"type":22},"2029-12-31",{"name":310,"class":112},"Singapore General Hospital",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":318,"targetDuration":320,"studyType":62,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":332},"100556658","drug-coated-balloon-compared-with-cutting-balloon-in-treatment-of-arteriovenous-fistula-stenosis-100556658","NCT06527963","DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis","Dragon","Inclusion Criteria:\n\nSubjects aged between 18 and 75 years. Subjects possess a mature upper limb autologous arteriovenous fistula (AVF) and have undergone at least one hemodialysis session.\n\nTarget lesion must be located in the venous segment of the upper limb AVF. Doppler ultrasound confirms that the target lesion stenosis is ≥50%, accompanied by at least one of the following clinical manifestations: elevated venous pressure during dialysis, abnormal fistula signs, significant reduction in blood flow (\\\u003C200ml\u002Fmin).\n\nGuidewire and balloon successfully pass through the lesion and complete dilation. 6.Subjects or their legal representatives must understand the purpose of the trial, voluntarily participate in the clinical trial, and sign an informed consent form, while also being willing to adhere to the specific follow-up schedules set by this trial.\n\nExclusion Criteria:\n\nTarget lesion located in the arterial segment or anastomosis of the AVF. Target lesion located in the lower limb AVF. Subjects with previous stent implantation in the AVF. Patients diagnosed with symptomatic central venous occlusive disease: AVF flow reduction accompanied by swelling of the ipsilateral limb, chest, or facial area, with DSA confirmation of central venous occlusive disease.\n\nSubjects with two or more target lesions in the AVF (when two stenoses are less than 3 cm apart, they are considered as one target lesion).\n\nSubjects with acute thrombosis in the AVF or who have undergone AVF thrombolysis or thrombectomy within the past 30 days.\n\nSubjects who have undergone or plan to undergo surgical intervention on the AVF within 30 days.\n\nSubjects with AVF infection or concurrent systemic active infection. Subjects planning renal transplantation or switching to peritoneal dialysis within the next 12 months.\n\nSubjects with diseases causing coagulopathy, such as thrombocytopenic purpura. Subjects undergoing immunotherapy or suspected\u002Fdiagnosed with vasculitis. Subjects with allergies or contraindications to heparin or contrast agents. Subjects who are pregnant or breastfeeding. Subjects with a life expectancy of less than 12 months.",{"count":319,"type":22},180,"12 Months","The purpose of this clinical trial is to compare the efficacy and safety of cutting balloons versus drug-coated balloons in treating venous stenosis of autologous arteriovenous fistulas.The main questions it aims to answer are:\n\n1. Will drug-coated balloons achieve a better CD-TLR rate compared to cutting balloons?\n2. What medical problems do participants have when receiving treatment with drug-coated balloons or cutting balloons?",[30,323,155],"Angioplasty, Balloon","2024-07-25",{"date":326,"type":43},"2024-07-30",{"date":328,"type":43},"2024-07-01",{"date":201,"type":22},{"name":331,"class":112},"RenJi Hospital",3]